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Treatment of AL amyloidosis (AL) with high dose
melphalan and autologous stem cell transplant (HDM/SCT)
results in a high rate of durable complete hematologic
responses (CHR) associated with systemic clinical responses
and improvement in survival. However, patients with cardiac
involvement are at increased risk of treatment-related
mortality (TRM).
HDM/SCT was performed for thirty patients between
2000 and 2011. Risk stratiﬁcation based on organ dysfunc-
tionwas performed. Analyses of pre and post SCT treatments,
TRM in patients with and without cardiac involvement,
hematologic (HR) and organ responses, progression free
(PFS) and overall survival (OS) was performed.
The median age was 60 years (range, 41-72) and there
were 20 males (67%). Twenty (67%) had multi-organ
involvement, 7 (24%) had single organ involvement, 18 (60%)
had renal involvement and 12 (40%) had cardiac involvement.
Peripheral blood stem cells were mobilized with G-CSF
alone for 3e4 days. HDM was administered over two days
and adjusted depending on age, severity of cardiac disease
and performance status. Twenty (67%) patients received 200
mg/m2, 9 (30%) received 140 mg/m2 and 1 received 100mg/
m2 HDM.
TRM, deﬁned as deaths within 100 days of SCT, occurred
in 3 patients (10%), 2 had cardiac disease and 1 did not. No
deaths occurred during stem cell mobilization. Of the 12
patients with cardiac involvement, 2 died within 100 days
(from CHF and sepsis with NYHA III and I prior to SCT). Of the
18 patients without cardiac involvement, 1 patient died of
exsanguination from AL-involved splenic rupture (Fisher's
exact test, P ¼ .54). Of the 12 patients with cardiac involve-
ment, 8 had a septal wall thickness >1.1cm and 6 were >
1.3cm. Of the 9 patients that had BNP measurements, all
were >100 pg/mL and 4 were >500 pg/mL.
Fourteen patients (47%) patients achieved CHR and 7
(23%) achieved at least a partial hematologic response at 1
year following HDM/SCT. Organ speciﬁc responses at 1 year
were conﬁrmed in 8 subjects. Fifteen patients received
chemotherapy prior to HDM/SCT leading to a deeper HR
prior to transplant in 7 patients. Two patients received a 2nd
autologous transplant, 4 and 7 years after the ﬁrst and
remain alive and in remission.Figure 1.HDM/SCT for patients with AL amyloidosis with and without
cardiac involvement is feasibleand is associatedwithexcellent
2 and 5 -year PFS and OS rates (Figure 1). Due to the inherent
ﬂaws in using traditional biomarkers and cardiac MRI for
staging cardiac disease in the setting of renal dysfunction,
improved strategies are needed. We are currently assessing
theutilityof speckle trackingderivedmyocardial strain indices
as a means for early diagnosis of cardiac involvement and
response to therapy- an area in which standard echocardio-
graphic measurements have been disappointing. Informative
data have been identiﬁed in the serial strain analyses on 5
patients who are currently undergoing therapy for AL.151
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Background: Nodular lymphocyte predominant Hodgkin
Lymphoma (NLPHL) is a more indolent form of Hodgkin
Lymphoma that is usually associated with favorable
outcomes. There are few reports of refractory disease
requiring high dose chemotherapy and autologous stem cell
transplantation (ASCT). Long-term follow up and outcomes
of refractory NLPHL requiring ASCT are lacking in the litera-
ture. The aim of this study was to describe clinical charac-
teristics of relapsed refractory NLPHL and outcomes
following ASCT in a cohort of patients followed at a single
institution.
Methods: The actively maintained Mayo Clinic Lymphoma
Database includes all consenting consecutive patients with
lymphoma seen at Mayo Clinic Rochester. This was used to
retrospectively identify patients with NLPHL. The study was
approved by the Institutional Review Board. Pathology was
conﬁrmed by a hematopathologist. The clinical characteris-
tics, therapy and outcomes of patients with NLPHL were
analyzed.
Results: Between 1970 and 2010, 222 consecutive adult
patients with NLPHL were identiﬁed. The median follow-up
for the entire cohort was 20 years. Forty-six (20.7%) relapsed
during the course of the disease and 17 (7.6%) developed
a transformation to diffuse large B cell lymphoma. Of the 46
patients, 8 (17.4%) had local relapses and were treated with
radiation therapy while 38 (82.6%) were treated with
chemotherapy (19 of these 38 patients had no prior exposure
to chemotherapy). Nine patients (4% of the entire cohort,
19.6% of relapsed patients) had ASCT. BEAM (BCNU, etopo-
side, cytarabine and melphalan) conditioning chemotherapy
was used in 6 (66.7%) patients. The median age of this group
was 29 years (21-52) and the median number of prior regi-
mens was two. All nine patients had prior exposure to ABVD
(Adriamycin, bleomycin, vinblastine, dacarbazine) and
salvage platinum based therapy was used in three patients
(33.3%). The median time from diagnosis to ASCT was 73
months (10-348). Two patients relapsed after ASCT (time to
relapse was 4 and 22 months). Seven patients (77.8%)
remained disease free after a median follow up of 70 months
(32-119). The median overall survival in this group
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year overall survival rate was 55.5%.
Conclusions: In our experience, ASCT was associated with
excellent disease control and outcomes in patients with
relapsed refractory LPHL.Table 1
Complete follow-up
(2 yrs)
Prophylaxis
until
neutrophil
recovery
Prophylaxis
for 6 months
Prophylaxis
for 1 year
Number 76 12 40
Median age (range) 54 (16-72) 52 (22-72) 55 (26-70)
Conditioning
Regimen:
Melphalan 41 (54%) 5 (42%) 25 (62%)
Myeloablative
chemotherapy
35 (46%) 7 (58%) 15(38%)
Autologous Stem
Cell Source:
Peripheral blood 68 (89%) 12 (100%) 39 (98%)
Bone marrow 6 (8%) 0 0
Both 2 (3%) 0 1 (2%)
Bortezomib use:
Prior to transplant 10 (13%) 5 (42%) 15 (38%)
Post transplant 5 (7%) 0 5 (12%)152
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Busulfan (Bu) is commonly used with cyclophosphamide
(Cy) as a conditioning regimen for HPCT. We previously re-
ported that substituting IV for oral Bu was associated with
less relapses and superior relapse free (RFS) and overall
survivals (OS) for relapsed or refractory NHL pts undergoing
AHPCT (Br J Haematol 2010;148:226-34). It is unknown
whether such a beneﬁt exists for IV Buwhen usedwith Cy for
AHPCT for plasma cell myeloma.We performed a prospective
studywith this regimenwithout Bu dose adjustment in order
to compare outcomes with historical controls who received
oral Bu at our institution. 55 pts were transplantedwith IV Bu
from 7/29/09-8/23/12 and 117 oral Bu pts were transplanted
from 3/22/94-4/6/06. IV Bu pts were older (P < 0.001), more
often had lower Karnofsky PS at HPCT (P< 0.001), more prior
therapies (P < 0.001), more advanced disease status at HPCT
(p¼0.002) and a longer median time from diagnosis to HPCT
(14 vs 8 mos, P < 0.001). More oral Bu pts received G-CSF
alone for mobilization therapy (90 vs 46%, P < 0.001), had
more days of apheresis (median 3 vs 2, P< 0.001) and higher
median CD34+ and TNC doses (7.22 vs 4.68 x 106/kg,
respectively, P< 0.001; 12.60 vs. 8.52 x 108/kg, respectively, P
< 0.001). There were no differences in time to neutrophil
engraftment, but platelet engraftment was more rapid for
oral Bu pts (median 11 vs 15 d, P < 0.001). Oral Bu pts had
signiﬁcantly more and worse mucositis by the modiﬁed
OMAS (66% vs. 0%, P < 0.001; median scores 0.2 vs. 0, P <
0.001). IV Bu pts had more infections (p¼0.034), but there
were no differences between the groups regarding CMV
infection, GI or pulmonary toxicity, relapse, relapse free
survival RFS or OS. At this time 46 (84%) of the IV Bu and 39
(33%) of the oral Bu pts are alive, however, the median follow
up was longer for the oral Bu pts (118 vs 13 mos, P < 0.001).
The median RFS and OS have not yet been observed in the IV
Bu group, but were 26 and 63 months, respectively for the
oral Bu pts. Disease relapse was the most common cause of
death for both the IV and oral Bu pts (67% and 77% of deaths).
1 and 2 year relapse mortality rates were 7% and 19% for IV
Bu pts and 7% and 22% for oral Bu pts. 1 and 2 year non-
relapse mortality rates were 5% and 12% for IV Bu and 4% and
4% for oral Bu. Death due to pulmonary toxicity occurred in 4
oral Bu pts and 0 IV Bu pts. Based upon these preliminary
results using IV instead of oral Bu decreases toxicity and
potentially improves safety as suggested from our ﬁnding of
signiﬁcantly less oral mucositis and no pulmonary deaths
with IV Bu. Further follow up of the IV Bu pts is required to
adequately assess for a survival beneﬁt. Investigation of PK
based Bu dosing strategies in this transplant setting may be
appropriate to help elucidate whether outcomes may be
further improved.153
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Introduction: Varicella-Zoster Virus (VZV) infection is
a relatively common cause of morbidity following autologous
hematopoietic cell transplant (auto-HCT). Previous guide-
lines recommended antiviral prophylaxis against VZV only
during the post HCT neutropenia period. The CDC in 2009
recommended extending VZV prophylaxis for 1 year post-
transplantation.
Methods:We retrospectively analyzed rates of VZV infection
following auto-HCTat our transplant center prior to and after
the implementation of extended acyclovir prophylaxis in
June 2008. We divided our study population into three
different cohorts according to the length of VZV prophylaxis:
(1) prophylaxis until neutrophil recovery to 500/uL (n¼76),
(2) prophylaxis for 6months (n¼12) or (3) 12months (n¼40)
post auto-HCT. All patients received acyclovir 400 mg oral or
iv twice daily or valacyclovir 500 mg oral daily. For patients
in whom VZV infection occurred, data was collected on
severity of infection, timing of onset, treatment of the reac-
tivation and any associated complications.
Results: 128 patients undergoing auto-HCT between January
1,2004 and January 31, 2010were included in the study. Table
1 demonstrates baseline characteristics for the three cohorts.
By Fisher's exact test, there was a signiﬁcant difference in
rates of VZV infection between the neutrophil recovery and
12months prophylaxis cohorts at 14% (n¼11) and 2% (n¼1)
(P¼0.03), respectively. VZV infection rate in the 6months
prophylaxis groupwas 16% (n¼2), but did not reach statistical
signiﬁcance due to small numbers. Median time to the onset
of VZV infection was 4 months (1-10 months) in the neutro-
phil recovery group, whereas only 1 event occurred in the 12
month prophylaxis group at 19-months post-transplant.
Complications observed with VZV infections include post-
